Methodik, die neugierig macht. Evidenz, die Entscheidungen trägt.
Medi First R&D develops cannabinoid-based therapy profiles aligned with clinical requirements - from the Target Product Profile (TPP) and formulation science to evidence generation (preclinical, observational, clinical).
- TPP logic: efficacy, tolerability, and dosability as defined development criteria
- Formulation science & bioavailability: liposomal systems, nano-emulsions, standardizable concepts
- Clinic & research loop: anonymized outcomes as input for protocols and safety monitoring
From therapeutic potential to methodological validation
The central hurdle in modern phytomedicine is the gap between therapeutic potential and a heterogeneous evidence base. Medi First R&D closes the gap between exploratory botany and highly regulated pharmacy. We translate uncertainty into reproducible quality - for well-founded clinical decisions and high patient safety in cannabinoid therapies.
Precision through patient-centered drug design
We work along a TPP (Target Product Profile) logic: clinical requirements are translated into defined target parameters. This creates a development path that can be validated.
Methodology
The 4-phase pathway
01
Profiling
stratified analysis of patient groups (e.g., pediatrics/geriatrics) and metabolic requirements.
02
TPP
definition of biochemical and formulation targets as guidance for development and assessment.
03
Prototyping
selection of targeted genetics and development of suitable drug-delivery systems (e.g., liposomes).
04
Validation
protocol-based evidence generation in preclinical models as well as via Real-World Data (RWD).
Validation through real-world care
Medi First R&D operates within an integrated data loop with the group’s own care network.
Anonymized real-world outcomes (RWD) feed directly into our hypothesis generation and safety monitoring in a GDPR-compliant manner. This translational approach enables drug development that derives clinical standards directly from real-world care and transfers them back into practice as validated therapy pathways.
Synergy of genetics, formulation science, and technology
Our platform combines genetics, formulation science, and drug-delivery approaches in an integrated development process. From the TPP-based selection of specific chemovars to the optimization of bioavailability (e.g., liposomal systems), reproducible profiles for clinical applications are created.
Cultivation is also aligned with the target profile: biophilic living-soil cultivation for complex metabolite profiles, and sterile aero-/hydroponic systems for highly standardized isolates and defined purity.
Clinical differentiation as a methodological standard.
Our research programs are guided by a stratified matrix for pediatrics, geriatrics, and functional pain therapy in adults. This differentiation enables precise drug design that translates biological variance directly into clinical safety.
Clinical safety meets research expertise
PhD candidate Gabriel Hentschel leads the scientific strategy at the interface of international research and clinical application. With deep expertise in neurology and clinical safety, he safeguards the methodological integrity of our development programs and moderates the responsible transfer of knowledge into medical practice.
More about the Scientific Lead
Collaboration
We work together with hospitals, universities, and industry partners on formulations, protocols, and evidence generation - from scoping through to study and implementation planning.
Our services
Joint studies
protocol design, outcome concepts, translational transfer
Co-development
from TPP through prototyping to the evidence plan.
Contract research
formulation, bioavailability, profiling/chemovar
More about collaborationsGet in touch now
Information on this website is intended for professional and collaboration partners. No medical advice and no individual therapy recommendations.
